SP140 protects immune cells and limits harmful interferon effects in tuberculosis

Tuberculosis remains an infection that challenges the immune system, producing lung lesions that require coordinated surveillance by immune cells. In new work led by corresponding author Emma Lefrançais, researchers asked why some immune responses intended to fight infection can instead cause tissue damage and weaken protective immunity. The study focused on a protein called SP140 and on the role of type I interferon signaling (IFN-I), a pathway known to influence inflammation and immune cell behavior. Using a mouse model of tuberculosis, the team examined how SP140 affects the balance between protective responses and damaging inflammation. By looking specifically at how immune cells behave inside infected lung tissue, they aimed to determine whether SP140 helps maintain effective T cell responses and overall host resistance. The work connects molecular control of inflammatory signaling to the ability of T cells to monitor and respond to infected lesions, framing SP140 as a potential guardian against an overactive IFN-I response that can undermine immunity.

The researchers used intravital microscopy to watch immune cells in real time inside infected lungs. This live imaging approach made it possible to see T cell dynamics and motility within lesions during infection. The team observed that when IFN-I signaling became exuberant, T cell movement and dynamics inside lesions were restricted, compromising lesion surveillance. Importantly, blocking the interferon receptor with IFNAR blockade fully restored T cell motility in these areas. Alongside the changes in movement, T cell numbers were also rescued when the harmful signaling was restrained. Taken together, these findings show that SP140 sustains host resistance in mice by restraining IFN-I-driven pathology; this restraint coincides with preserved T cell immunity and lesion surveillance. The study therefore links a specific regulator, SP140, with both control of IFN-I effects and maintenance of functional T cell responses in infected lung tissue.

The results highlight a mechanism by which the immune system can avoid self-inflicted damage while still fighting infection. By limiting IFN-I-driven pathology, SP140 helps preserve the ability of T cells to move through and monitor infected lesions, which is essential for mounting an effective defense. Restoring T cell motility and numbers by blocking IFNAR demonstrates that excessive interferon signaling is a reversible contributor to immune dysfunction in this model. For researchers and clinicians, these insights point to the importance of balancing inflammatory signals during tuberculosis: too much IFN-I response can be damaging, whereas appropriate restraint — as mediated by SP140 — supports protective immunity. While the work was conducted in mice, it lays a conceptual foundation for exploring whether targeting similar pathways can preserve T cell function and improve resistance in human tuberculosis without directly altering antimicrobial treatments.